Conditions: Hodgkin Lymphoma Anaplastic Large-cell Lymphoma
Keywords: Lymphoma Hodgkin Anaplastic Large-cell Relapsed Refractory Antigens, CD30 Antibody-Drug Conjugate Antibodies, Monoclonal Lymphoma, Non-Hodgkin Lymphoma, Large-Cell, Anaplastic Monomethyl auristatin E Drug Therapy Immunotherapy Hematologic Diseases
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 20
Healthy volunteers: no

Brief summary:
This is an open-label trial to estimate the concentrations of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma (HL) or relapsed/refractory systemic anaplastic large cell lymphoma (sALCL) participants treated with either brentuximab vedotin or brentuximab vedotin + rifampicin.

Detailed description:

Arms:
arm 1: Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg. arm 2: Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg beginning on Cycle 1, Day 1; daily rifampicin (600 mg PO) will be administered during Cycles 0 through 3 only, beginning on Cycle 0, Day 1 (7 days before the Cycle 1, Day 1 dose of brentuximab vedotin) and continuing through Cycle 3, Day 21.

Interventions: intervention 1: brentuximab vedotin intervention 2: Brentuximab vedotin and rifampicin
Intervention descriptions: intervention 1: Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg. intervention 2: Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg beginning on Cycle 1, Day 1; daily rifampicin (600 mg PO) will be administered during Cycles 0 through 3 only, beginning on Cycle 0, Day 1 (7 days before the Cycle 1, Day 1 dose of brentuximab vedotin) and continuing through Cycle 3, Day 21.

Protocol document: